{
    "clinical_study": {
        "@rank": "55562", 
        "brief_summary": {
            "textblock": "OBJECTIVES:\n\n      I.  Compare the efficacy of plasmapheresis and human immunoglobulin infusion in minimizing\n      morbidity and augmenting the pace of recovery in children with Guillain-Barre syndrome.\n\n      II.  Compare the potential risks, in terms of treatment related side effects and adverse\n      clinical outcome, between these two treatment modalities."
        }, 
        "brief_title": "Randomized Study of Plasmapheresis or Human Immunoglobulin Infusion in Childhood Guillain-Barre Syndrome", 
        "condition": "Guillain-Barre Syndrome", 
        "condition_browse": {
            "mesh_term": "Guillain-Barre Syndrome"
        }, 
        "detailed_description": {
            "textblock": "PROTOCOL OUTLINE:\n\n      This is a randomized, multicenter study.\n\n      Patients are randomized to receive either human immunoglobulin infusion (IVIg) (arm I) or\n      plasmapheresis (arm II).\n\n      Arm I patients receive liquid heat-treated IVIg for 4 days starting on day 1 and then\n      another single infusion of IVIg on day 7, 8, or 9.\n\n      Arm II patients receive serial plasmapheresis treatments.  The first exchange is given on\n      day 1 and the remaining exchanges are given over the next 5-10 days.\n\n      Patients are followed at weeks 1, 2, 3, 4, 8, 12, and 24."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "PROTOCOL ENTRY CRITERIA:\n\n        --Disease Characteristics--\n\n        Guillain-Barre syndrome (GBS): Progressive weakness of two or more limbs; Absence or\n        reduced tendon reflexes; No atypical symptoms of GBS (e.g., Miller-Fisher variant); No\n        pure sensory neuropathy; No prior history of GBS\n\n        Disability at least grade 3 according to Guillain-Barre Study Group grading scale (unable\n        to walk 5 meters without assistance); Must not have improvement of one or more disability\n        grades prior to randomization in this study\n\n        No paresthesias, numbness, or weakness that began more than 14 days before randomization\n        in this study\n\n        No CNS involvement\n\n        --Prior/Concurrent Therapy--\n\n        Biologic therapy: No prior treatment with plasmapheresis or infusion of human\n        immunoglobulin (IVIg)\n\n        Endocrine therapy: No concurrent corticosteroids or other immunosuppressants (except for\n        concurrent medical conditions, e.g., asthma)\n\n        Radiotherapy: Not specified\n\n        Surgery: Not specified\n\n        Other: No concurrent mechanical ventilation\n\n        --Patient Characteristics--\n\n        Age: Under 18 but with at least 3 months of independent walking\n\n        Hematopoietic: Cerebrospinal fluid leukocyte count less than 50/mm3\n\n        Hepatic: No liver failure\n\n        Renal: No kidney failure\n\n        Neurological: No other major neurologic diseases, other neuromuscular disorders, or\n        cerebral palsy\n\n        Other: HIV negative; No contraindications to plasmapheresis or IVIg; No severe\n        uncontrolled infection; No known IgA hypersensitivity; No other preexisting disease that\n        would interfere with assessment of disability grades; No other causes of acquired weakness\n        (e.g., poliomyelitis, botulism, or other etiologies); No diabetes; Not pregnant"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "17 Years", 
            "minimum_age": "N/A"
        }, 
        "enrollment": "170", 
        "firstreceived_date": "February 24, 2000", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00004833", 
            "org_study_id": "199/13444", 
            "secondary_id": [
                "EUSM-076-97", 
                "EUSM-FDR001265"
            ]
        }, 
        "intervention": {
            "intervention_name": "Immune globulin", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Antibodies", 
                "Immunoglobulins"
            ]
        }, 
        "keyword": [
            "Guillain-Barre syndrome", 
            "demyelinating neuropathy", 
            "neurologic and psychiatric disorders", 
            "rare disease"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "overall_official": {
            "affiliation": "Emory University", 
            "last_name": "John T. Sladky", 
            "role": "Study Chair"
        }, 
        "overall_status": "Suspended", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "N/A", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00004833"
        }, 
        "source": "FDA Office of Orphan Products Development", 
        "sponsors": {
            "collaborator": {
                "agency": "Emory University", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "FDA Office of Orphan Products Development", 
                "agency_class": "U.S. Fed"
            }
        }, 
        "start_date": "July 1995", 
        "study_design": "Allocation: Randomized, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2002"
    }, 
    "geocoordinates": {}
}